INTREPID Alliance Forms Scientific Advisory Board
The INTREPID Alliance, a consortium comprised of innovative biopharmaceutical companies, is focused on advancing antiviral treatments to bolster global health in preparation for future pandemics. Recently, the alliance has officially announced the formation of its Scientific Advisory Board (SAB), which will be pivotal in steering efforts toward accelerating the discovery and development of antiviral therapies against emerging viral agents.
Objectives of the Scientific Advisory Board
The primary focus of the SAB will be to provide expert guidance to INTREPID regarding antiviral research priorities. Its members, composed of distinguished professionals in infectious disease research, drug development, and public health, will advise on emerging trends in the field, help shape program strategies, and tackle significant scientific challenges.
Strategic Endeavors for Pandemic Preparedness
By interpreting vital landscape data and utilizing their expertise, the SAB will enhance INTREPID's long-term strategies aimed at improving preparedness for pandemics. This initiative is crucial as the world continues to face new viral threats, making it imperative for the scientific community to work collaboratively.
Introducing the Chair of the Board
Leading the advisory board is Ruxandra Draghia-Akli, M.D., Ph.D., who was appointed earlier this year. Dr. Draghia-Akli boasts an impressive background in public health, with a history of developing pioneering healthcare solutions. She is set to become the Executive Vice President and Head of Research and Development at Novavax.
Dr. Draghia-Akli’s Vision for Antiviral Research
In her inaugural message, Dr. Draghia-Akli expressed her excitement about her new role and emphasized the importance of antiviral treatments in bolstering global defenses against viruses. She voiced a strong commitment to addressing current gaps in the antiviral pipeline. Her goal is to work with INTREPID and its esteemed SAB members to enhance the research and development landscape for viral treatments, ensuring better readiness for future health crises.
Meet the Members of the Advisory Board
The SAB features an array of accomplished individuals, each bringing unique expertise and experience to the table:
Dr. Constance Benson
A clinician and researcher recognized for her work in HIV and tuberculosis, Dr. Benson is a Professor of Medicine and Global Public Health at the University of California San Diego. She has been pivotal in managing major clinical trials and is dedicated to advancing viral health treatments.
Dr. Kelly Chibale
Holding the Neville Isdell Chair in African-centric Drug Discovery, Dr. Chibale is a Professor at the University of Cape Town. His research is focused on discovering new drugs for infectious diseases, with a spotlight on improving health outcomes for populations of African descent.
Dr. Barry Clinch
A consultant with extensive experience in clinical development strategy, Dr. Clinch has worked in the biopharmaceutical sector for 25 years and has played a key role in the development of vaccines and antivirals.
Dr. Ken Duncan
As the Deputy Director of Discovery and Translational Sciences at the Gates Foundation, Dr. Duncan focuses on drug discovery programs, particularly in tuberculosis and malaria, addressing significant global health challenges.
Dr. Daria Hazuda
A veteran in infectious disease research, Dr. Hazuda is currently at Generate:Biomedicines. Her history at Merck was instrumental in the development of crucial antiviral therapies and vaccines.
Dr. Johan Neyts
Professor of Virology at KU Leuven, Dr. Neyts specializes in creating antiviral treatments and is known for his contributions in the field of neglected viral infections.
About the INTREPID Alliance
The INTREPID Alliance aims to expedite the development of innovative treatments for viral pandemic agents. By consolidating knowledge from the public and private sectors, the alliance is positioned to address critical gaps in antiviral solutions, ensuring effective responses to future threats. The launch of the INTREPID Alliance reflects a proactive approach in engaging a wide range of stakeholders dedicated to public health.
Frequently Asked Questions
What is the purpose of the INTREPID Alliance?
The INTREPID Alliance is focused on accelerating the development of treatments for viral pandemic agents, ensuring the world is prepared for future threats.
Who chairs the Scientific Advisory Board?
Dr. Ruxandra Draghia-Akli is the inaugural chair of the Scientific Advisory Board, bringing extensive experience in public health.
What expertise do the SAB members have?
The SAB comprises experts in virology, infectious diseases, drug discovery, and public health, contributing to a wide-ranging knowledge base.
How will the SAB support pandemic preparedness?
The SAB will guide research priorities, inform strategies, and enhance collaboration to ensure robust responses to viral threats.
Why are antiviral treatments important?
Antiviral treatments are crucial for protecting global health, providing defense against both emerging and existing virus threats.
